VitaSpring Biomedical Co. Ltd.
VSBC
$0.01
-$0.24-95.56%
OTC PK
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -38.15% | -28.82% | -14.04% | 28.28% | 102.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -38.15% | -28.82% | -91.57% | 28.28% | 102.64% |
| Operating Income | 38.15% | 28.82% | 94.59% | -28.28% | -102.64% |
| Income Before Tax | 38.15% | 28.82% | 94.59% | -27.79% | -102.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 38.15% | 28.82% | 94.58% | -69.92% | -145.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 38.15% | 28.82% | 94.58% | -69.92% | -145.39% |
| EBIT | 38.15% | 28.82% | 94.59% | -28.28% | -102.64% |
| EBITDA | 38.19% | 28.76% | 94.67% | -28.80% | -104.92% |
| EPS Basic | 35.29% | 33.33% | 94.53% | -57.14% | -142.86% |
| Normalized Basic EPS | 36.36% | 22.22% | 94.44% | -16.67% | -120.00% |
| EPS Diluted | 35.29% | 33.33% | 94.53% | -57.14% | -142.86% |
| Normalized Diluted EPS | 36.36% | 22.22% | 94.44% | -16.67% | -120.00% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.24% | 0.25% | 0.25% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.24% | 0.25% | 0.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |